JP4544746B2 - 置換された１，３−ジアリール−２−ピリド−２−イル−３−（ピリド−２−イルアミノ）プロパノール誘導体、その製造方法、それを含有する医薬およびその使用 - Google Patents
置換された１，３−ジアリール−２−ピリド−２−イル−３−（ピリド−２−イルアミノ）プロパノール誘導体、その製造方法、それを含有する医薬およびその使用 Download PDFInfo
- Publication number
- JP4544746B2 JP4544746B2 JP2000574510A JP2000574510A JP4544746B2 JP 4544746 B2 JP4544746 B2 JP 4544746B2 JP 2000574510 A JP2000574510 A JP 2000574510A JP 2000574510 A JP2000574510 A JP 2000574510A JP 4544746 B2 JP4544746 B2 JP 4544746B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- acid
- cycloalkyl
- conh
- alkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- AFYIEOJPAUYNOZ-FQXGQDRMSA-N CC(C)(C)OC(NCCCC[C@H](C(N[C@H](CCCCNC(OC(C)(C)C)=O)C(Nc1c(C(C(C(c2ccccc2)O)c2ccccn2)Nc2ncccc2)cccc1)=O)=O)N)=O Chemical compound CC(C)(C)OC(NCCCC[C@H](C(N[C@H](CCCCNC(OC(C)(C)C)=O)C(Nc1c(C(C(C(c2ccccc2)O)c2ccccn2)Nc2ncccc2)cccc1)=O)=O)N)=O AFYIEOJPAUYNOZ-FQXGQDRMSA-N 0.000 description 1
- 0 CC1(*)C=C(NC(C(C(*)O)C(N=*)=CC=CC=C*)c2ccccc2N*)N=CC=C1 Chemical compound CC1(*)C=C(NC(C(C(*)O)C(N=*)=CC=CC=C*)c2ccccc2N*)N=CC=C1 0.000 description 1
- MDQJTCDAAMLRLH-UHFFFAOYSA-N [O-][N+](c1c(C(C(C(c2ccccc2)O)c2ccccn2)Nc2ncccc2)cccc1)=O Chemical compound [O-][N+](c1c(C(C(C(c2ccccc2)O)c2ccccn2)Nc2ncccc2)cccc1)=O MDQJTCDAAMLRLH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19845406.6 | 1998-10-02 | ||
| DE19845406A DE19845406C2 (de) | 1998-10-02 | 1998-10-02 | Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| PCT/EP1999/006933 WO2000020393A1 (de) | 1998-10-02 | 1999-09-18 | Substituierte 1,3-diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)-propanolderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002526530A JP2002526530A (ja) | 2002-08-20 |
| JP2002526530A5 JP2002526530A5 (enExample) | 2006-09-07 |
| JP4544746B2 true JP4544746B2 (ja) | 2010-09-15 |
Family
ID=7883187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000574510A Expired - Fee Related JP4544746B2 (ja) | 1998-10-02 | 1999-09-18 | 置換された１，３−ジアリール−２−ピリド−２−イル−３−（ピリド−２−イルアミノ）プロパノール誘導体、その製造方法、それを含有する医薬およびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6596728B1 (enExample) |
| EP (1) | EP1117642B1 (enExample) |
| JP (1) | JP4544746B2 (enExample) |
| KR (1) | KR100609255B1 (enExample) |
| CN (1) | CN1173951C (enExample) |
| AR (1) | AR021845A1 (enExample) |
| AT (1) | ATE267809T1 (enExample) |
| AU (1) | AU757689B2 (enExample) |
| BR (1) | BR9915027B1 (enExample) |
| CA (1) | CA2345985C (enExample) |
| CZ (1) | CZ299569B6 (enExample) |
| DE (2) | DE19845406C2 (enExample) |
| DK (1) | DK1117642T3 (enExample) |
| ES (1) | ES2219066T3 (enExample) |
| HU (1) | HU226688B1 (enExample) |
| ID (1) | ID29249A (enExample) |
| PL (1) | PL205034B1 (enExample) |
| PT (1) | PT1117642E (enExample) |
| RU (1) | RU2224748C2 (enExample) |
| TR (1) | TR200100896T2 (enExample) |
| WO (1) | WO2000020393A1 (enExample) |
| ZA (1) | ZA200102587B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2431995A1 (en) | 2000-12-21 | 2002-06-27 | Aventis Pharma Deutschland Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| DE10064402A1 (de) * | 2000-12-21 | 2002-06-27 | Aventis Pharma Gmbh | Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| JP2005505538A (ja) * | 2001-08-22 | 2005-02-24 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | アリール置換プロパノールアミン誘導体と他の活性成分との組み合わせ物およびその使用 |
| US7161008B2 (en) * | 2002-05-03 | 2007-01-09 | Sanofi - Aventis Deutschland GmbH | Optically active β-aminoketones, optically active 1,3-amino alcohols and processes for preparing them |
| DE10219987A1 (de) * | 2002-05-03 | 2004-04-08 | Aventis Pharma Deutschland Gmbh | Optisch aktive β-Aminoketone, optisch aktive 1,3-Aminoalkohole und Verfahren zu deren Herstellung |
| GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
| US7816353B2 (en) * | 2003-10-24 | 2010-10-19 | Exelixis, Inc. | P70S6 kinase modulators and method of use |
| EP4137137A1 (en) | 2010-05-26 | 2023-02-22 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| EA038594B1 (ru) | 2011-10-28 | 2021-09-21 | Шайр Хьюман Дженетик Терапис, Инк. | Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени |
| JP6217938B2 (ja) | 2011-10-28 | 2017-10-25 | ルメナ ファーマシューティカルズ エルエルシー | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 |
| KR20160002773A (ko) | 2013-03-15 | 2016-01-08 | 루메나 파마수티컬즈, 인코포레이티드 | 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제 |
| AU2014229050A1 (en) | 2013-03-15 | 2015-10-22 | Lumena Pharmaceuticals Llc | Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease |
| JP6361168B2 (ja) * | 2013-06-17 | 2018-07-25 | Jsr株式会社 | 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物 |
| EP4424363B1 (en) | 2019-02-12 | 2026-04-29 | Mirum Pharmaceuticals, Inc. | Methods for increasing growth in pediatric subjects having cholestatic liver disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0000816A1 (en) * | 1977-08-06 | 1979-02-21 | Beecham Group Plc | Substituted amino-pyridine derivatives, processes for their preparation and pharmaceutical compositions containing them |
| SU1194273A3 (ru) * | 1981-02-09 | 1985-11-23 | Пфайзер Инк (Фирма) | Способ получени пирбутерола или его аналогов |
| GB9203347D0 (en) * | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
| ES2098570T3 (es) * | 1992-02-22 | 1997-05-01 | Hoechst Ag | Amidas de un acido 4-amino-2-ureido-pirimidina-5-carboxilico, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su utilizacion. |
| DE19845402B4 (de) * | 1998-10-02 | 2005-04-07 | Aventis Pharma Deutschland Gmbh | Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| ATE268758T1 (de) | 1997-04-04 | 2004-06-15 | Aventis Pharma Gmbh | Hypolipidämische propanolaminderivate |
| DE19845405C2 (de) * | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Arylsubstituierte Propanolaminderivate und deren Verwendung |
-
1998
- 1998-10-02 DE DE19845406A patent/DE19845406C2/de not_active Expired - Fee Related
-
1999
- 1999-09-18 PT PT99948791T patent/PT1117642E/pt unknown
- 1999-09-18 TR TR2001/00896T patent/TR200100896T2/xx unknown
- 1999-09-18 CN CNB99811636XA patent/CN1173951C/zh not_active Expired - Fee Related
- 1999-09-18 ES ES99948791T patent/ES2219066T3/es not_active Expired - Lifetime
- 1999-09-18 WO PCT/EP1999/006933 patent/WO2000020393A1/de not_active Ceased
- 1999-09-18 DK DK99948791T patent/DK1117642T3/da active
- 1999-09-18 CZ CZ20011152A patent/CZ299569B6/cs not_active IP Right Cessation
- 1999-09-18 BR BRPI9915027-1A patent/BR9915027B1/pt not_active IP Right Cessation
- 1999-09-18 KR KR1020017004096A patent/KR100609255B1/ko not_active Expired - Fee Related
- 1999-09-18 JP JP2000574510A patent/JP4544746B2/ja not_active Expired - Fee Related
- 1999-09-18 AU AU61926/99A patent/AU757689B2/en not_active Ceased
- 1999-09-18 PL PL347096A patent/PL205034B1/pl unknown
- 1999-09-18 AT AT99948791T patent/ATE267809T1/de active
- 1999-09-18 HU HU0103533A patent/HU226688B1/hu not_active IP Right Cessation
- 1999-09-18 EP EP99948791A patent/EP1117642B1/de not_active Expired - Lifetime
- 1999-09-18 ID IDW20010736A patent/ID29249A/id unknown
- 1999-09-18 CA CA2345985A patent/CA2345985C/en not_active Expired - Fee Related
- 1999-09-18 RU RU2001111841/04A patent/RU2224748C2/ru not_active IP Right Cessation
- 1999-09-18 DE DE59909606T patent/DE59909606D1/de not_active Expired - Lifetime
- 1999-09-30 AR ARP990104960A patent/AR021845A1/es active IP Right Grant
- 1999-10-01 US US09/410,083 patent/US6596728B1/en not_active Expired - Lifetime
-
2001
- 2001-03-29 ZA ZA200102587A patent/ZA200102587B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6596728B1 (en) | Substituted 1,3-diaryl-2-pyrid-2-yl-3-(pyrid-2-ylamino)propanol derivatives, process for their preparation, pharmaceuticals comprising these compounds and their use | |
| TW200845981A (en) | Compounds and compositions as channel activating protease inhibitors | |
| FI70415B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara petider | |
| JP4598953B2 (ja) | 脂質代謝障害を治療するための胆汁酸と結合したプロパノールアミン誘導体 | |
| JPH07508748A (ja) | ヒト白血球エラスターゼに対する阻害剤としてのフッ素含有ジペプチド | |
| JP2022501364A (ja) | グルコース感受性インスリンおよびその使用 | |
| JP2006515563A (ja) | 抗インテグリン活性を有するフルオロ−アルキル−シクロペプチド誘導体 | |
| JPH06172287A (ja) | アミノカルボン酸誘導体及び該化合物を含有する医薬組成物 | |
| MXPA01003145A (en) | Propanolamine derivatives substituted with heterocyclic compounds, methods for their production, pharmaceutical compositions containing said compounds and the use thereof | |
| CZ20011151A3 (cs) | Deriváty propanolaminu vázané s kyselinou žlučovou pro léčení poruch metabolismu lipidů | |
| JPS60190795A (ja) | ペプタイド | |
| JPH09227554A (ja) | ニューロキニンから誘導された新規な偽ペプチド類、それらの製造方法及びそれらを含む医薬組成物 | |
| JPH07228565A (ja) | スパガリン類縁体及びその用途 | |
| GB1596535A (en) | Biologically-active peptides | |
| JPH02273696A (ja) | ペプチドおよびこれを含有する抗痴呆剤 | |
| MXPA01003207A (en) | Propanolamine derivatives linked with bile acid used for treating disorders of the lipid metabolism | |
| JPH0789986A (ja) | ジペプチド誘導体及びそれを有効成分とする骨疾患の予防及び治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060720 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060720 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090929 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091222 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100312 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100312 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100330 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100422 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100622 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100629 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130709 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |